Phaseline

Targets › IKZF1

IKZF1 (DNA-binding protein Ikaros): drug programs, companies and trials

3 programs from 3 companies in 14 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Transcription regulator of hematopoietic cell differentiation. Binds gamma-satellite DNA. Plays a role in the development of lymphocytes, B- and T-cells. (UniProt, Q13422)

Open in Phaseline: the race on IKZF1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbGolcadomide (CC-99282, BMS-986369)
Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader
CRBN, IKZF1, IKZF3Phase 3Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin …Apr 2027
AlumisEnvudeucitinib (ESK-001)
Oral PROTAC degrader of Ikaros (IKZF1)
IKZF1, TYK2Phase 3Plaque Psoriasis; SLESep 2027
Abdullah KhanCC-92480
IKZF1/IKZF3 degrader
IKZF1, IKZF3Phase 1Recurrent Multiple MyelomaDec 2026

Conditions

Plaque Psoriasis (2) SLE (1) Large B-cell Lymphoma (1) Follicular Lymphoma (1) Lymphoma, Follicular (1) Lymphoma, Non-Hodgkin (1) Lymphoma, B-Cell (1) Diffuse Large B-cell Lymphoma Refractory (1) Follicular Lymphoma Stage II (1) B-Cell Non-Hodgkin Lymphoma-Recurrent (1) Peripheral T Cells Lymphoma (PTCL) (1) Recurrent Mantle Cell Lymphoma (1)

Modalities

mixed (2), small molecule (1)

Companies

Alumis (1) Bristol-Myers Squibb (1) Abdullah Khan (1)

Related targets

IKZF3 (2) TYK2 (1) CRBN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.